XLS.SW Xlife Sciences AG
- Market cap
- CHF 48.6M
- P/E
- -
- P/B
- 0.42x
- ROE
- -7.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is XLS.SW undervalued?
Graham numberThe Graham number of Xlife Sciences AG cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Xlife Sciences AG fundamental analysis
No fundamental analysis for Xlife Sciences AG yet.
Xlife Sciences AG stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Xlife Sciences AG
Xlife Sciences AG focuses on the development and commercialization of research projects in the life sciences sector. The company's project covers technology platforms, biotechnology/therapies, medical technology, and artificial intelligence/digital health areas that focuses on identifying new therapeutic approaches and biomarkers for common diseases based on human genetic data; and offers clinical research services. It also develops novel treatment options in specific indica…
Full company profileXlife Sciences AG financial statements
Xlife Sciences AG annual financial statements (CHF; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | 515K | 397K | 806K | 1.03M | 988K | 835K | 275K |
| Gross Profit | 179K | -25.6K | 359K | 186K | 449K | 550K | 9.32K |
| Operating Income | -768K | -3.09M | -5.23M | -21.0M | -20.3M | -19.3M | -31.6M |
| EBITDA | - | - | - | 20.7M | 20.9M | 40.5M | -3.05M |
| Net Income | 1.05M | 21.5M | 53.4M | 14.3M | 14.9M | 34.3M | -21.5M |
| EPS | 0.28 | 5.16 | 11 | 2.71 | 2.66 | 5.97 | -3.74 |
| Balance Sheet | |||||||
| Total Assets | 154M | 186M | 480M | 490M | 512M | 540M | 517M |
| Total Liabilities | 56.6M | 55.5M | 269M | 255M | 244M | 235M | 145M |
| Shareholders' Equity | 97.4M | 130M | 211M | 235M | 268M | 305M | 287M |
| Cash & Short-term Investments | 2.54M | 4.70M | 1.96M | 221K | 219K | 99.0K | 404K |
| Cash Flow | |||||||
| Operating Cash Flow | -398K | -402K | -4.32M | -4.61M | 172K | -422K | -903K |
| Capital Expenditure | 24.9K | 222K | 1.21M | 80.2K | 41.1K | 12.1K | 372K |
| Free Cash Flow | - | -624K | -5.54M | -4.69M | 131K | -434K | -1.28M |
| Ratios | |||||||
| ROE | 1.1% | 16.5% | 25.3% | 6.1% | 5.5% | 11.2% | -7.5% |
| ROA | 0.7% | 11.6% | 11.1% | 2.9% | 2.9% | 6.3% | -4.2% |
| Net Profit Margin | 204.0% | 5,408.4% | 6,627.0% | 1,392.3% | 1,505.3% | 4,105.6% | -7,826.5% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Xlife Sciences AG dividends
Xlife Sciences AG has not paid dividends in the last 7 fiscal years.
Who owns Xlife Sciences AG
- Insiders 48.50%
- Institutions 4.53%
- Public & others 46.97%
- Shares outstanding 5.77M
- Free float 2.99M
Xlife Sciences AG company profile
- Company name
- Xlife Sciences AG
- Ticker
- XLS.SW
- ISIN
- CH0461929603
- Exchange
- SIX Swiss Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 20
- Fiscal year end
- December
- Address
- Talacker 35, Zurich, Switzerland, 8001
- Phone
- 41 44 385 84 60
- Website
- xlifesciences.ch
About Xlife Sciences AG
Xlife Sciences AG focuses on the development and commercialization of research projects in the life sciences sector. The company's project covers technology platforms, biotechnology/therapies, medical technology, and artificial intelligence/digital health areas that focuses on identifying new therapeutic approaches and biomarkers for common diseases based on human genetic data; and offers clinical research services. It also develops novel treatment options in specific indication areas; focuses in the areas of medical technology to develop innovative methods for diagnosing illnesses and/or patient monitoring; and deploys artificial intelligence to improve diagnostic methods and/or processes in the field of biotechnology. Xlife Sciences AG was founded in 2019 and is headquartered in Zurich, Switzerland.
Xlife Sciences AG management
7- Mr. Oliver R. BaumannCEO & Executive Director · born 1988
- Mr. Carl von HalemChief Financial Officer
- Mr. Beat KlauiHead of Accounting & Taxation
- Dr. Alexander ZinkChief Scientific Officer
- Dr. Dennis FinkSenior Communications & Investor Relations Manager
- Mr. Christian FaberHead of Legal & Compliance
- Dr. Frank PlogerManaging Director of Xlife Sciences USA